The Centers for Disease Control and Prevention (CDC) will no longer recommend its PCR test to detect the CCP virus, saying that it will withdraw the test’s emergency use authorization (EUA), and instead, encourage labs to use a multiplex assay that can detect and differentiate the virus from the flu. “Given the availability of commercial options, CDC intends to discontinue support for the CDC 2019 Novel Coronavirus (2019 nCoV) Real-Time RT-PCR Diagnostic Panel, the assay first introduced in February 2020 for detection of SARS-CoV-2,” Jasmine Reed, public affairs specialist at the CDC, told The Epoch Times via email. She added that “… the demand for this test has declined with the emergence of other higher-throughput and multiplexed assays. CDC is encouraging pubic health laboratories (PHL) to adopt the CDC Influenza SARS-CoV-2 (Flu SC2) Multiplex Assay to enable continued surveillance for both influenza and SARS-CoV-2, which will save both time and …